Inhibitors



## Flucytosine-<sup>13</sup>C,15N<sub>2</sub>

 Cat. No.:
 HY-B0139S

 CAS No.:
 1216616-31-7

 Molecular Formula:
 C<sub>3</sub>13CH<sub>4</sub>FN15N<sub>2</sub>O

Molecular Weight: 132.07

Target: Isotope-Labeled Compounds

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Flucytosine- $^{13}$ C, $^{15}$ N <sub>2</sub> (NSC 103805- $^{13}$ C, $^{15}$ N <sub>2</sub> ; Ro 2-9915- $^{13}$ C, $^{15}$ N <sub>2</sub> ) is a $^{13}$ C- and $^{15}$ N-labeled Flucytosine (HY-B0139).
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Vermes A, et al. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000 Aug;46(2):171-9.

[2]. Te Dorsthorst DT, et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother. 2002 Sep;46(9):2982-9.

[3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA